Xin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xin Wang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Bihu Gao
Affiliation Department of Nephrology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
1 shared publicationHong Zhu
Affiliation Department of Nephrology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
1 shared publication- Qin Yang
Department of Internal Medicine, Affiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Dalian, China
1 shared publication - Shuai Han
Affiliation Department of Nephrology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
1 shared publication Wenwen Chu
Affiliation Department of Nephrology, The First Affiliated Hospital of Wannan Medical College, Wuhu, China
1 shared publicationYu Li
Department of Nephrology, The Affiliated Zhong Shan Hospital of Dalian University, Dalian, 116001, P.R. China
1 shared publication
Latest Publications
- 1 October 2023
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 23 (18) , 1838-1844
Advances in Exercise Therapy in Hemodialysis: A Systematic Review
Background: The main and common treatment of renal replacement therapy (RRT) for chronic kidney disease (CKD), especially in end-stage kidney disease (ESKD) patients, is hemodialysis (HD). Many reports have shown that exercise therapy is good for HD patients. This review aims to describe recent advances in exercise therapy in HD patients. Objective: Our key opinions have focused on varied types of exercise therapy and identified barriers to exercise therapy among HD patients. Exercise implementation includes aerobic exercise training, resistance exercise training, combined exercise training, and novel exercise interventions. Barriers include internal and external distress, such as HD patients' restrictions and environmental problems. Methods: This review is based on the novel/ most findings in PubMed, Web of Science, Google Scholar, and MEDLINE from the inception of every database until August 2022. Results: The systematic search strategy identified 6 articles that met the inclusion criteria. Four were specific to exercise therapy in HD, and three were to exercise barriers in HD. Massive evidence has demonstrated exercise therapy for HD has specific benefits and neglectful causes of exercise barriers. Conclusion: In this review, we aimed to summarize recent advances in individual exercise therapy recommendations (type, intensity, time, and frequency) and exercise barriers in HD patients. In conclusion, Low/moderate-intensity exercise trained for at least thirty minutes five times per week, including aerobic exercise (Walking, Jogging, Swimming, and Health Exercises), resistance training (Dumbbells, Band training, and Knee extension), and combination exercise (both) during the first 2 hours of dialysis treatment or non-dialysis days is advisable treatment recommendation.
- 1 October 2023
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 23 (18) , 1838-1844
Advances in Exercise Therapy in Hemodialysis: A Systematic Review
Background: The main and common treatment of renal replacement therapy (RRT) for chronic kidney disease (CKD), especially in end-stage kidney disease (ESKD) patients, is hemodialysis (HD). Many reports have shown that exercise therapy is good for HD patients. This review aims to describe recent advances in exercise therapy in HD patients. Objective: Our key opinions have focused on varied types of exercise therapy and identified barriers to exercise therapy among HD patients. Exercise implementation includes aerobic exercise training, resistance exercise training, combined exercise training, and novel exercise interventions. Barriers include internal and external distress, such as HD patients' restrictions and environmental problems. Methods: This review is based on the novel/ most findings in PubMed, Web of Science, Google Scholar, and MEDLINE from the inception of every database until August 2022. Results: The systematic search strategy identified 6 articles that met the inclusion criteria. Four were specific to exercise therapy in HD, and three were to exercise barriers in HD. Massive evidence has demonstrated exercise therapy for HD has specific benefits and neglectful causes of exercise barriers. Conclusion: In this review, we aimed to summarize recent advances in individual exercise therapy recommendations (type, intensity, time, and frequency) and exercise barriers in HD patients. In conclusion, Low/moderate-intensity exercise trained for at least thirty minutes five times per week, including aerobic exercise (Walking, Jogging, Swimming, and Health Exercises), resistance training (Dumbbells, Band training, and Knee extension), and combination exercise (both) during the first 2 hours of dialysis treatment or non-dialysis days is advisable treatment recommendation.
- Open Access
- 20 October 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (10) , e0258736
Urinary proteomics investigations into contrast-induced acute kidney injury
Some patients have a decline in renal function after contrast medium injection, and this phenomenon is called contrast-induced acute kidney injury (CI-AKI); a small number of people even suffer severe renal failure. To date, the mechanism of CI-AKI remains unclear. We aimed to identify novel potential biomarkers in the urine of patients with CI-AKI through LC-MS/MS and bioinformatics analysis. We enrolled patients who underwent coronary angiography (contrast agent: iohexol). The CI-AKI group included 4 cases, and the non-CI-AKI group included 20 cases. We mixed the 4 CI-AKI samples and 20 non-CI-AKI samples. Then, a 0.6 ml urine sample was used for proteome analysis with LC-MS/MS approach. Metascape, ExPASy, and the Human Protein Atlas were utilized for bioinformatics analysis. We obtained 724 and 830 urine proteins from the CI-AKI and non-CI-AKI groups, respectively. The distribution of the pI values and molecular weights (MWs) of postoperative urine proteins showed no significant difference between the CI-AKI group and the non-CI-AKI group. A total of 99differentially expressed proteins (DEPs) were detected, among which 18 proteins were detected only in tubule cells, and 19 proteins were detected in both tubule cells and glomeruli. With GO analysis, the GEPs were mainly associated with immune response and inflammation. Although biomarkers cannot be asserted from this single pilot study, our results may help advance the understanding of the mechanisms of CI-AKI and identify potential novel biomarkers for further investigation.
- 20 October 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (10) , e0258736
Open AccessUrinary proteomics investigations into contrast-induced acute kidney injury
Some patients have a decline in renal function after contrast medium injection, and this phenomenon is called contrast-induced acute kidney injury (CI-AKI); a small number of people even suffer severe renal failure. To date, the mechanism of CI-AKI remains unclear. We aimed to identify novel potential biomarkers in the urine of patients with CI-AKI through LC-MS/MS and bioinformatics analysis. We enrolled patients who underwent coronary angiography (contrast agent: iohexol). The CI-AKI group included 4 cases, and the non-CI-AKI group included 20 cases. We mixed the 4 CI-AKI samples and 20 non-CI-AKI samples. Then, a 0.6 ml urine sample was used for proteome analysis with LC-MS/MS approach. Metascape, ExPASy, and the Human Protein Atlas were utilized for bioinformatics analysis. We obtained 724 and 830 urine proteins from the CI-AKI and non-CI-AKI groups, respectively. The distribution of the pI values and molecular weights (MWs) of postoperative urine proteins showed no significant difference between the CI-AKI group and the non-CI-AKI group. A total of 99differentially expressed proteins (DEPs) were detected, among which 18 proteins were detected only in tubule cells, and 19 proteins were detected in both tubule cells and glomeruli. With GO analysis, the GEPs were mainly associated with immune response and inflammation. Although biomarkers cannot be asserted from this single pilot study, our results may help advance the understanding of the mechanisms of CI-AKI and identify potential novel biomarkers for further investigation.
- Open Access
- 7 January 2021
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 75 (6) , e14011
A case report of rhabdomyolysis caused by the use of roxadustat in the treatment caused by renal anaemia
Case presentation: In this case, we share a case of one of our patients developed rhabdomyolysis after he was administered roxadustat to treat anaemia caused by chronic renal failure.Discussion: More than 1.2 million people died from chronic kidney damage (CKD) globally, in 2017. Anaemia is a common complication of CKD. Roxadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. Roxadustat is often used to treat anaemia caused by renal failure. Its adverse effects include high blood pressure, myocardial infarction, heart failure, high potassium, and dizziness; however, there are no reports about rhabdomyolysis associated with roxadustat.Conclusion: Physicians should be alert about the occurrence of rhabdomyolysis when roxadustat is used.
- 7 January 2021
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 75 (6) , e14011
Open AccessA case report of rhabdomyolysis caused by the use of roxadustat in the treatment caused by renal anaemia
Case presentation: In this case, we share a case of one of our patients developed rhabdomyolysis after he was administered roxadustat to treat anaemia caused by chronic renal failure.Discussion: More than 1.2 million people died from chronic kidney damage (CKD) globally, in 2017. Anaemia is a common complication of CKD. Roxadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. Roxadustat is often used to treat anaemia caused by renal failure. Its adverse effects include high blood pressure, myocardial infarction, heart failure, high potassium, and dizziness; however, there are no reports about rhabdomyolysis associated with roxadustat.Conclusion: Physicians should be alert about the occurrence of rhabdomyolysis when roxadustat is used.